CERO

CERo Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 2

Price Hits New Low

Price Hits 52-week low

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About CERO

Cero Therapeutics Holdings, Inc.

An innovative cancer immunotherapy company

Industry

Biological Technology

Established Date

09/23/2016

Listing Date

11/26/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cero.bio

Security Type

Common stock

Office address

201 Haskings Way, Suite 230, South San Francisco, CA 94080

Business

Introduction

CERo Therapeutics Holdings, Inc., was incorporated in Delaware on September 23, 2016. CERo is an innovative immunotherapy company driving the development of next-generation engineered T-cell therapies to treat cancer. Its proprietary T-cell engineering approach enables it to integrate certain ideal features of innate and adaptive immunity into a single therapeutic structure designed to mobilize the body's entire immune pool for optimized cancer therapy.

Company Financials

EPS

CERO has released its 2022 Q2 earnings. EPS was reported at 0.00, versus the expected 0.00, meeting expectations. The chart below visualizes how CERO has performed over recent quarters, highlighting trends in earnings surprises.